The disease itself — by whatever name — remains present in the world today, though at dramatically lower prevalence than in earlier centuries. The WHO reported approximately 174,000 new cases globally in 2019, with the highest burden in South and Southeast Asia, Brazil, and parts of Africa. Modern treatment with multidrug therapy can cure the disease and prevent disability if started early, and the duration of treatment required has shortened over the decades. The long historical period when leprosy was considered essentially incurable ended in stages: first with the chaulmoogra ester treatments that Ball developed, then with dapsone, then with multidrug therapy. Each transition improved outcomes and reduced transmission.

 

The stigma, however, has been more resistant to treatment than the disease itself. Discrimination against people with Hansen’s disease continues to be documented in countries where the disease remains prevalent. Leprosy colonies established in the nineteenth and early twentieth centuries in various countries continued operating long after effective treatments were available, in some cases maintained by institutional inertia and social exclusion rather than by any medical rationale. The United States itself maintained the National Leprosarium at Carville, Louisiana, as a facility for American Hansen’s disease patients from 1894 until 1999 — more than half a century after dapsone made indefinite confinement medically unjustifiable.

 

Understanding this context is essential to understanding why Ball’s work mattered so much to Hollmann. He was not simply trying to treat a skin disease. He was trying to find a way to discharge patients from confinement — to demonstrate, with a medically recoverable patient in front of him, that the legal and social framework of mandatory isolation was no longer warranted. A treatment that could clear the bacteria and produce clinical recovery was an argument, made in living patients, against the entire system of Kalaupapa.

ADVERTISEMENT
Advertisement
Share.